LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Home・Lista de Ações・Pacific Biosciences of California Inc

Pacific Biosciences of California Inc

Fechado

SetorSaúde

1.21 -4.72

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.2

Máximo

1.29

Indicadores-chave
By Trading Economics
Rendimento	32M -8.3M
Vendas	-7.5M 37M
EPS	-0.12
Margem de lucro	-22.258
Funcionários	485
EBITDA	509K -38M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+87.4% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-60M 421M
Abertura anterior	5.93
Fecho anterior	1.21

Sentimento de Notícias

By Acuity

50%

162 / 346 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

1.13 / N/A Suporte e Resistência

Pacific Biosciences of California Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

13 de mai. de 2026, 22:54 UTC

Ganhos

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 de mai. de 2026, 23:51 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

13 de mai. de 2026, 23:51 UTC

Conversa de Mercado

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 de mai. de 2026, 23:45 UTC

Conversa de Mercado

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 de mai. de 2026, 23:45 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

13 de mai. de 2026, 23:17 UTC

Ganhos

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 de mai. de 2026, 23:16 UTC

Ganhos

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 de mai. de 2026, 23:15 UTC

Ganhos

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 de mai. de 2026, 23:14 UTC

Ganhos

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 de mai. de 2026, 23:02 UTC

Conversa de Mercado

Ganhos

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 de mai. de 2026, 22:59 UTC

Conversa de Mercado

Ganhos

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 de mai. de 2026, 22:24 UTC

Ganhos

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 de mai. de 2026, 22:23 UTC

Ganhos

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 de mai. de 2026, 22:23 UTC

Ganhos

Xero FY International Revenue Growth 47%>XRO.AU

13 de mai. de 2026, 22:22 UTC

Ganhos

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 de mai. de 2026, 22:19 UTC

Ganhos

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 de mai. de 2026, 22:19 UTC

Ganhos

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 de mai. de 2026, 22:18 UTC

Ganhos

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 de mai. de 2026, 22:16 UTC

Ganhos

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 de mai. de 2026, 22:15 UTC

Ganhos

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 de mai. de 2026, 22:15 UTC

Ganhos

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 de mai. de 2026, 22:13 UTC

Ganhos

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 de mai. de 2026, 22:12 UTC

Ganhos

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 de mai. de 2026, 22:11 UTC

Ganhos

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 de mai. de 2026, 22:11 UTC

Ganhos

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 de mai. de 2026, 22:10 UTC

Ganhos

Xero Did Not Declare a Dividend>XRO.AU

13 de mai. de 2026, 22:10 UTC

Ganhos

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 de mai. de 2026, 22:09 UTC

Ganhos

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 de mai. de 2026, 22:00 UTC

Ganhos

Cisco to Shed Jobs for All-In AI Push -- Update

13 de mai. de 2026, 21:11 UTC

Ganhos

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Comparação entre Pares

Variação de preço

Pacific Biosciences of California Inc Previsão

Preço-alvo

By TipRanks

87.4% parte superior

Previsão para 12 meses

Média 2.38 USD 87.4%

Máximo 3 USD

Mínimo 1.5 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Pacific Biosciences of California Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

4 ratings

Comprar

Manter

Vender

Com base em 4 analistas que deram avaliações de ações para Pacific Biosciences of California Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

1.13 / N/ASuporte e Resistência

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Sentimento

By Acuity

162 / 346 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.